JP $MRK continue to see adjuvant as a potential upside driver to longer term Keytruda estimates. Merck provided updates for its clinical program adjuvant/neoadjuvant indications (~20 studies running) that could represent upside for Keytruda longer term.   From MRK slidedeck https://t.co/QO9VsPFdiW